Description
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-anti-virus–C90H140N34O19S2—-[1]H Tamamura, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1897-902.|[2]Stéphanie Gravel, et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem. 2010 Dec 3;285(49):37939-43.–368874-34-4–2066.42–99.90–O=C1[C@@]2([H])N(CCC2)C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N1)CC3=CC=C(C=C3)O)=O)CCCNC(N)=N)=O)CCCNC(N)=O)=O)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@@H](N)CCCNC(N)=N)=O)=O)CC4=CC5=C(C=CC=C5)C=C4)=O)=O)CC6=CC=C(C=C6)O)=O)CCCNC(N)=O)=O)CCCCN)=O)CCCNC(N)=O)=O–Cancer; Infection–DMSO : 25 mg/mL (ultrasonic)–CXCR;HIV–CXCR4;CXCR7;HIV–Anti-infection;GPCR/G Protein;Immunology/Inflammation–Peptides
